Summary

Eligibility
for people ages 18-101 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Official Title

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

Keywords

Carcinoma, Non-Small-Cell Lung, EGFR mutated, CD73, A2AR, Oleclumab, MEDI9447, AZD4635, Osimertinib, NSCLC, Immunotherapy, Non-Small-Cell Lung Carcinoma

Eligibility

Locations

  • Research Site
    San Francisco California 94143 United States
  • Research Site
    La Jolla California 92093 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedImmune LLC
Links
D6070C00004 redacted protocol D6070C00004 SAP redacted D6070C00004 CSR Synopsis redacted
ID
NCT03381274
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
About 43 people participating
Last Updated